Neue Podcast-Episode: Einblicke in Entstehung, Technologie und den klinischen Nutzen von CompagOs.

Gian Nutal Schädli discusses how 3D-printed bone models can support early diagnostics, drug testing, and regenerative medicine.

17 December 2024 – Press ReleaseSwiss researchers want to develop the world’ s first semi-automated machine for producing biomechanically loaded in vitro bone models to detect bone metastases from blood samples. The Bon3OID™ -MSP project, a collaboration between life science start-up CompagOs AG, Swiss technology innovation center CSEM, and the University of Fribourg (UniFr), has been approved by Innosuisse. The total project costs exceed CHF 750’000.

We are thrilled to announce that we are now an officially registered supplier on Scientist.com! This enhances our global visibility, making it easier for researchers and industry professionals to access and book our cutting-edge services.

We are excited to announce that CompagOs has received an investment from Kickfund, a prominent backer of Switzerland’s leading deep-tech startups. Renowned for backing startups that have participated in the prestigious Venturekick competition, Kickfund has recognized our potential to make a significant contribution to the tech landscape. With their support, we will continue to drive innovation and take CompagOs to new heights.

We are thrilled to announce that CompagOs has been awarded an Innovation Cheque from the Swiss Innovation Agency Innosuisse. This significant support will enable us to kickstart the expansion of our capacity for scaling up the production of our Bon3OID™ models, in collaboration with the Swiss Center for Electronics and Microtechnology (CSEM).

Our CEO Dr. Gian Nutal Schädli discusses bone organoids, mechanical loading, and translational bone cancer research on X-Health.show.

We are excited to share that CompagOs won first place in the Public Value cluster at the HSG Alumni Gründerpitch during the HSG Alumni Deutschlandkonferenz in Stuttgart in October 2023.

CompagOs is proud to announce its victory in Venture Kick’s final stage for 150k CHF, impressing the jury with Bon3OID™s’ potential in personalizing treatments in the bone domain. The funds will be used to advance both business and technology development. Additionally, this milestone significantly expands our network through the Kick Foundation and enhances our prospects for further funding.